Avoid late-stage failures by incorporating biomarkers in protocol design

Strategies to make clinical trials more efficient continue to be an industry focus — for faster time to market, to reduce costs and to deliver much-needed treatments.

Incorporating biomarker-based strategies during the study design phase can improve enrollment, help target treatments to patients that will receive the most benefit and shorten trial timelines.

Download this report to:

  • Understand how biomarkers are being used in oncology clinical trials.
  • Explore insights into historical oncology trial trends to monitor the effectiveness of strategies.
  • Evaluate how you can incorporate biomarkers in your clinical trials.